Senior Credit Analyst, Lucror Analytics

Leonard Law, CFA

Senior Credit Analyst

High Yield Experts

Lucror Analytics

Lucror Analytics is a leading credit and ESG research specialist and a provider of technology solutions for differentiated fixed income strategies. Our roots are in bottom-up fundamental credit analysis with a specialization in high yield corporate credits from Europe, Asia and Latin America. We are one of few research specialists integrating ESG considerations with fundamental credit research through a dedicated ESG platform. Our ESG assessment covers five key criteria: Disclosure, E,S, & G Pillars, Controversies, ESG Impact on Credit and ESG Momentum.

Recognizing the importance and value-add of Factor Investing in fixed income, Lucror developed the Smart Quant Navigator (SQN), an intuitive platform that helps clients devise and implement factor-based strategies ranging from pure quant to active fundamental, with integrated ESG.

Our company has been at the forefront of developments in the fixed income markets, identifying opportunities and consistently delivering new products and value-adding solutions to clients. Lucror has close relationships with the largest and most reputable asset managers, family offices, hedge funds, investment and wealth managers globally.

Credit

<ul>
<li>In today's Morning Views publication we comment on developments of the following high yield issuers: Genting Berhad, Bharti Airtel, Japfa Comfeed</li>
<li>In the US, the Dallas Fed manufacturing index improved to negative 3.0 in October (-9.4 e / -9.0 p).</li>
<li>Treasuries slid yesterday, with yields up 3-5 bps following a soft auction of 2Y and 5Y notes. The yield on the 2Y UST rose 3 bps to 4.14%, while that on the 10Y UST was up 4 bps at 4.28%. Equities edged higher, with the S&amp;P 500 and Nasdaq both rising 0.3% at 5,824 and 18,567, respectively.</li>
</ul>


In today's Morning Views publication we comment on developments of the following high yield issuers: Genting Berhad, Bharti Airtel, Japfa Comfeed
In the US, the Dallas Fed manufacturing index improved to negative 3.0 in October (-9.4 e / -9.0 p).
Treasuries slid yesterday, with yields up 3-5 bps following a soft auction of 2Y and 5Y notes. The yield on the 2Y UST rose 3 bps to 4.14%, while that on the 10Y UST was up 4 bps at 4.28%. Equities edged higher, with the S&amp;P 500 and Nasdaq both rising 0.3% at 5,824 and 18,567, respectively.


India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>Naveen Jindal Group to Invest INR 2,160 Crore in Cement Expansion</li>
<li>Bharti Airtel Secures CCI Nod to Raise Stake in Indus Towers</li>
<li>Reliance Infrastructure to Invest INR 10,000 Crore in Defence Manufacturing</li>
</ul>


Naveen Jindal Group to Invest INR 2,160 Crore in Cement Expansion
Bharti Airtel Secures CCI Nod to Raise Stake in Indus Towers
Reliance Infrastructure to Invest INR 10,000 Crore in Defence Manufacturing


# 67 India Insight: Reliance Infra in Defence, Bharti Airtel CCI Nod, Naveen Jindal Cement Expansion

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Rubicon Research Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/rubicon-research-limited" target="_blank" data-smartkarma-citation="entities:43796:1" rel="noopener">Rubicon Research Limited (1453591D IN)</a> is looking to raise about US$130m in its India IPO.</li>
<li>It is a pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States.</li>
<li>In this note, we talk about the company’s historical performance.</li>
</ul>



Rubicon Research Limited (1453591D IN) is looking to raise about US$130m in its India IPO.
It is a pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States.
In this note, we talk about the company’s historical performance.


Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth

External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Tariff Hike by Jio and Bharti Airtel: Jio and Bharti Airtel (Bharti) will be benefitted from tariff hikes and customer gains however we expect private telcom companies to report QoQ decline in their subscriber base.</li><li>However, the loss is likely to be more at the lower end, i.e., the non-data subs of Airtel/VIL/Hexacom and entry-level subs of Jio (non-JioPhone; Jio has kept JioBharat tariffs unchanged) choosing to shift to BSNL.</li><li>We still expect Bharti/Hexacom to report QoQ increase in 4G subsbase and Jio to see a decline, as its entire base is 4G. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Tariff Hike by Jio and Bharti Airtel: Jio and Bharti Airtel (Bharti) will be benefitted from tariff hikes and customer gains however we expect private telcom companies to report QoQ decline in their subscriber base.However, the loss is likely to be more at the lower end, i.e., the non-data subs of Airtel/VIL/Hexacom and entry-level subs of Jio (non-JioPhone; Jio has kept JioBharat tariffs unchanged) choosing to shift to BSNL.We still expect Bharti/Hexacom to report QoQ increase in 4G subsbase and Jio to see a decline, as its entire base is 4G. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Shiva Pharmachem Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shiva-pharmachem-limited" target="_blank" data-smartkarma-citation="entities:40109:1" rel="noopener">Shiva Pharmachem Limited (9155347Z IN)</a> is looking to raise around US$110m in its India IPO.</li>
<li>It is a manufacturer in the Indian specialty chemicals business and was the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India, as per Frost&amp;Sullivan .</li>
<li>In this note, we talk about the company’s historical performance.</li>
</ul>



Shiva Pharmachem Limited (9155347Z IN) is looking to raise around US$110m in its India IPO.
It is a manufacturer in the Indian specialty chemicals business and was the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India, as per Frost&amp;Sullivan .
In this note, we talk about the company’s historical performance.


Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

India

Bharti Airtel Limited, a part of Bharti Enterprises, provides telecommunications services throughout India. The Company provides GSM Mobile Services, broadband, fixed line telephone services, long distance services (international & national) and enterprise services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bharti Airtel (BHARTI IN)

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: Genting Berhad, Bharti Airtel, Japfa Comfeed

Lucror Analytics

# 67 India Insight: Reliance Infra in Defence, Bharti Airtel CCI Nod, Naveen Jindal Cement Expansion

Major Indian companies making significant investments in various sectors to expand and strengthen their presence in the market.

Sudarshan Bhandari

Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth

Rubicon Research Limited is looking to raise about US$130m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Q2FY25 Earnings Preview - Telecom

We still expect Bharti/Hexacom to report QoQ increase in 4G subsbase and Jio to see a decline, as its entire base is 4G.

Axis Direct

Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

Shiva PharmaChem is looking to raise around US$110m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: Genting Berhad, Bharti Airtel, Japfa Comfeed

Lucror Analytics

# 67 India Insight: Reliance Infra in Defence, Bharti Airtel CCI Nod, Naveen Jindal Cement Expansion

​Major Indian companies making significant investments in various sectors to expand and strengthen their presence in the market.

Sudarshan Bhandari

Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth

Rubicon Research Limited is looking to raise about US$130m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Q2FY25 Earnings Preview - Telecom

We still expect Bharti/Hexacom to report QoQ increase in 4G subsbase and Jio to see a decline, as its entire base is 4G.

Axis Direct

Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

Shiva PharmaChem is looking to raise around US$110m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Major Indian companies making significant investments in various sectors to expand and strengthen their presence in the market.